Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1143220 | 1.00 | KCNA5 (0.68) | KCNA5KDM4ELMNAMAPK1DPP4 | |
| SCHEMBL1143218 | 1.00 | KCNA5 (0.68) | KCNA5KDM4ELMNAMAPK1DPP4 | |
| SCHEMBL1153036 | 0.86 | KCNA5 (0.54) | KCNA5KDM4ELMNAMAPK1ADRA2A | |
| SCHEMBL17045047 | 0.86 | KCNA5 (0.54) | KCNA5KDM4ELMNAMAPK1DPP4 | |
| SCHEMBL17045046 | 0.86 | KCNA5 (0.54) | KCNA5KDM4ELMNAMAPK1DPP4 | |
| SCHEMBL1153033 | 0.86 | KCNA5 (0.54) | KCNA5KDM4ELMNAMAPK1ADRA2A | |
| SCHEMBL1153251 | 0.83 | KCNA5 (0.51) | KCNA5ALDH1A1MEN1KMT2A | |
| SCHEMBL1153248 | 0.83 | KCNA5 (0.51) | KCNA5ALDH1A1MEN1KMT2A | |
| SCHEMBL8958995 | 0.82 | KCNA5 (0.53) | KCNA5KDM4ELMNAMAPK1DPP4 | |
| SCHEMBL9120791 | 0.82 | KCNA5 (0.53) | KCNA5KDM4ELMNAMAPK1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103265528-B | Esomeprazole magnesium preparation method | HUNAN QIANJIN XIANGJIANG PHARM CO LTD | 2015-05-06 | — | — | CN | claimed |
| CN-103265528-A | Esomeprazole magnesium preparation method | HUNAN QIANJIN XIANGJIANG PHARM CO LTD | 2013-08-28 | — | — | CN | claimed |
| CN-103265528-B | Esomeprazole magnesium preparation method | HUNAN QIANJIN XIANGJIANG PHARM CO LTD | 2015-05-06 | — | — | CN | disclosed |
| CN-103265528-A | Esomeprazole magnesium preparation method | HUNAN QIANJIN XIANGJIANG PHARM CO LTD | 2013-08-28 | — | — | CN | disclosed |
| US-7943799-B2 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110046415-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| US-7842839-B2 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-7612236-B2 | Method for producing optically active bisamidoalcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| EP-0895992-B1 | Copper complexes of optically active bisoxazolines as enantioselective catalysts in cyclopropanation reactions | SUMITOMO CHEMICAL CO (JP) | 2009-06-10 | — | — | EP | disclosed |
| US-20080200672-A1 | Highly enantioselective carbonyl reduction with borane catalyzed by chiral spiroborate esters derived from chiral beta-aminoalcohols | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-08-21 | — | — | US | disclosed |
| US-20080200672-A1 | Highly enantioselective carbonyl reduction with borane catalyzed by chiral spiroborate esters derived from chiral beta-aminoalcohols | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-08-21 | — | — | US | disclosed |
| EP-1213293-A1 | Use of chiral, uncharged metal compounds as doting agents for liquid crystals | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| EP-0735142-B1 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICALS CO LTD (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-20010027162-A1 | Transition metal compound, catalyst component for olefin polymerization, catalyst for olefin polymerization, and process for producing olefinic polymer | HIRAHATA WATARU (JP) | 2001-10-04 | — | — | US | disclosed |
| US-6242377-B1 | POLYMERIZATION IN PRESENCE OF BISOXAZOLINE WITH NICKEL, COBALT, PALLADIUM, RHODIUM, RUTHENIUM, ALUMINUM AND BORON COMPLEXES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-06-05 | — | — | US | disclosed |
| US-6072081-A | Optically active bisoxazoline compounds, production and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-06-06 | — | — | US | disclosed |
| EP-0942010-A1 | Transition metal compounds, catalyst components and catalysts for olefin polymerization, and process for producing olefinic polymers | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-09-15 | — | — | EP | disclosed |
| EP-0895992-A2 | Copper complexes of optically active bisoxazolines as enantioselective catalysts in cyclopropanation reactions | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-02-10 | — | — | EP | disclosed |
| US-5717116-A | TREATING A MIXTURE OF PHENYLHALOGENOMETHYLCARBINOLS WITH A LIPASE IN THE PRESENCE OF A CARBOXYLATE FOLLOWED BY CYCLIZATION WITH A BASE | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 1998-02-10 | — | — | US | disclosed |
| EP-0735142-A2 | Process for producing (R)-styrene oxides | SUMIKA FINE CHEMICAL COMPANY, LTD. (JP) | 1996-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046415-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | CYP3A7, GRK7, CYP2A7 | KCNA5 2187/4885KDM4E 3354/4885LMNA 1389/4885 |
| US-20080200672-A1 | Highly enantioselective carbonyl reduction with borane catalyzed by chiral spiroborate esters derived from chiral beta-aminoalcohols | ADH1A, ALDH7A1, HSD11B1 | KCNA5 2048/4885KDM4E 2187/4885LMNA 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.